Protein Expression FAQs

KREX™ utilises baculovirus expression system for the production of proteins of interest in insect cells. Although producing these recombinant baculoviruses are technically laborious, it may offers many advantages over other traditional systems: 1) Safety – baculoviruses are nonpathogenic, 2) Ease to scale-up – insect cell suspension cultures allows large-scale protein production in bioreactors, 3) Size – accomodate large genes, 4) High levels of protein expression – variety of efficient gene promoters and 5) Post-translational modification – proper protein folding, glycosylation, phosphorylation, acetylation and acylation.

KREX™ protein expression system utilises insect cell known as Sf9, a clonal isolate derived from the parental Spodoptera frugiperda cell line IPLB-Sf-21-AE.

Yes, we have successfully expressed proteins using different protein expression systems. Please email us at [email protected] for further discussion.

Depending on the size and complexity of the protein, the duration may vary between 3-6 months. Please email us at [email protected] for further discussion.

The cost is largely dependent on the size and the nature of the protein. Please email us at [email protected] for further discussion.

Crude lysates are subjected to SDS-PAGE and the biotinylated proteins were detected via Western blot.

Our final product is crude protein lysates. However purified proteins are also available at an additional cost, please contact us at [email protected].

Please email us at [email protected] for further information.

FEATURED PRODUCTS

IMMUNOME
Protein Array

High-throughput
sero-profiling platform

CTA
Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Custom
Protein Array

Flexible format for
high-throughput screening

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

2008 – 2020© Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X